<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-0255</journal-id>
<journal-title><![CDATA[Revista Archivo Médico de Camagüey]]></journal-title>
<abbrev-journal-title><![CDATA[AMC]]></abbrev-journal-title>
<issn>1025-0255</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Camagüey]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-02552020000600008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Fludarabina en el tratamiento del linfoma no Hodgkin folicular]]></article-title>
<article-title xml:lang="en"><![CDATA[Fludarabine in the treatment of follicular non-Hodgkin lymphoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Laguarda]]></surname>
<given-names><![CDATA[Yaimé]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Laguna-Salvia]]></surname>
<given-names><![CDATA[Leonardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Larquin-Comet]]></surname>
<given-names><![CDATA[José Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León-Ramentol]]></surname>
<given-names><![CDATA[Cira Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Camagüey Hospital Universitario Manuel Ascunce Domenech Departamento de Transfusiones]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Holguín Hospital Universitario Lucia Iñiguez Landín Servicio de Hematología]]></institution>
<addr-line><![CDATA[Holguín ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Ciencias Médicas de Camagüey Centro de Inmunología y Productos Biológicos (CENIPBI) ]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<numero>6</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-02552020000600008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-02552020000600008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-02552020000600008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento: el linfoma no Hodgkin folicular ocupa el segundo lugar entre los linfomas no Hodgkin de estirpe B, se caracterizan por un patrón de remisiones y recaídas continuas. La fludarabina constituye una opción de tratamiento del mismo al lograr una rápida remisión, con disminución del porciento de recaída.  Objetivo:  evaluar la fludarabina como tratamiento de rescate del linfoma no Hodgkin folicular.  Métodos:  se realizó un estudio observacional analítico de cohortes, longitudinal prospectivo concurrente. El universo de estudio lo conformaron los pacientes que acudieron a la consulta de Hematología con diagnóstico de linfoma no Hodgkin folicular y quedó constituido por 63 pacientes, de los cuales 21 seleccionados mediante muestreo no probabilístico intencionado que recibieron tratamiento con fludarabina, conformaron cohorte de expuestos, que se compararon con 42 pacientes con similares características que recibieron otros esquemas de poliquimioterapia que no incluyó la fludarabina y que constituyó la cohorte de no expuestos.  Resultados:  fue mayor el número de pacientes con más de 50 años y del sexo masculino, perteneciente al estadio IV de Cotswold y los que tuvieron un riesgo de recaída de bajo - intermedio. El tiempo de sobrevida libre de enfermedad fue mayor en los tratados con fludarabina quienes presentaron menos complicaciones.  Conclusiones: en los pacientes tratados con la fludarabina como tratamiento de rescate del linfoma folicular el tiempo de sobrevida libre de la enfermedad fue mayor y se presentaron menos complicaciones, lo que demuestra su utilidad como tratamiento de primeria línea en ausencia del rituximab.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  follicular non-Hodgkin's lymphoma occupies the second place among non-Hodgkin's lymphomas of line B, they are characterized by a pattern of continuous remissions and relapses. Fludarabine constitutes a treatment option for the same as it achieves a rapid remission, with a decrease in the percentage of relapse.  Objective:  to evaluate fludarabine as a rescue treatment for follicular non-Hodgkin lymphoma.  Methods:  a concurrent prospective longitudinal, analytical, observational cohort study was conducted. The study universe was made up of patients who attended the Hematology consultation with a diagnosis of follicular non-Hodgkin's lymphoma and consisted of 63 patients, of which 21 were selected by intentional non-probabilistic sampling who received treatment with fludarabine, made up a cohort of exposed, these were compared with 42 patients with similar characteristics who received other poly-chemotherapy regimens that did not include fludarabine and they constituted the unexposed cohort.  Results:  the number of male patients over 50 years of age, belonging to Cotswold stage IV, and those with a low-intermediate risk of relapse was greater. The disease-free survival time was longer in those treated with fludarabine, who had fewer complications.  Conclusions:  in patients treated with fludarabine as rescue treatment for follicular lymphoma, the disease-free survival time was longer and there were fewer complications, which show its usefulness as a first-line treatment in the absence of rituximab.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[LINFOMA NO HODGKIN/tratamiento farmacológico]]></kwd>
<kwd lng="es"><![CDATA[LINFOMA NO HODGKIN/terapia]]></kwd>
<kwd lng="es"><![CDATA[LINFOMA FOLICULAR/diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[RECURRENCIA]]></kwd>
<kwd lng="es"><![CDATA[ESTUDIO OBSERVACIONAL]]></kwd>
<kwd lng="en"><![CDATA[LYMPHOMA, NON-HODGKIN/drug therapy]]></kwd>
<kwd lng="en"><![CDATA[LYMPHOMA, NON-HODGKIN/therapy]]></kwd>
<kwd lng="en"><![CDATA[LYMPHOMA, FOLLICULAR/diagnosis]]></kwd>
<kwd lng="en"><![CDATA[RECURRENCE]]></kwd>
<kwd lng="en"><![CDATA[OBSERVATIONAL STUDY]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno Laguarda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Laguna Salvia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Larquin Comet]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[León Ramentol]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez Soler]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
<name>
<surname><![CDATA[González Basulto]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criterios diagnósticos y nuevas opciones terapéuticas para los pacientes con diagnóstico de Linfoma no Hodgkin]]></article-title>
<source><![CDATA[Arch méd Camagüey]]></source>
<year>2019</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>415-26</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Mauch]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aster]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Non-Hodgkin&#8217;s lymphoma. En: De Vita VT, Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology]]></source>
<year>2015</year>
<edition>10 th</edition>
<page-range>1552-83</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams&amp;Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skrabek]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Seftel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of nonhodgkin lymphoma]]></article-title>
<source><![CDATA[Transfus Apher Sci]]></source>
<year>2013</year>
<volume>49</volume>
<page-range>133-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticos de Salud</collab>
<source><![CDATA[Anuario estadístico de salud 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maddocks]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Epperla]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Karmali]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Umyarova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies]]></article-title>
<source><![CDATA[American journal of hematology]]></source>
<year>2017</year>
<volume>92</volume>
<page-range>161-70</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner-Johnston]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Byrtek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of transformed follicular lymphoma in the modern era: a report from the National Lympho Care Study (NLCS)]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2015</year>
<volume>126</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>851-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Mariño]]></surname>
<given-names><![CDATA[OL]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Mariño]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda Chaviano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización clínico-epidemiológica de los linfomas en un período de cinco años en Villa Clara]]></article-title>
<source><![CDATA[Medicent Electrón]]></source>
<year>2015</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grover]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel targeted agents in Hodgkin and non-Hodgkin lymphoma therapy]]></article-title>
<source><![CDATA[Pharmaceuticals (Basel, Switzerland)]]></source>
<year>2015</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>607-36</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorge]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[McDaniel]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeted Therapies for the Treatment of Non-Hodgkin Lymphomas: Present and Future]]></article-title>
<source><![CDATA[Pharmaceuticals]]></source>
<year>2016</year>
<volume>9</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>6-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novoa]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Beñaran]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rojo]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Cuña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iriondo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monofosfato de fludarabina como primera línea en el tratamiento de los síndromes linfoproliferativos crónicos. Estudio multicéntrico, Uruguay 1997-2012]]></article-title>
<source><![CDATA[Rev Hematol]]></source>
<year>2013</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Cancerología</collab>
<source><![CDATA[ESE-Guía de Práctica Clínica para la detección, tratamiento y seguimiento de linfoma Hodgkin y no Hodgkin en población mayor de 18 años]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud y Protección Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Danglot Banck]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vega Franco]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cómo seleccionar una prueba estadística]]></article-title>
<source><![CDATA[Rev Mex Pediatr]]></source>
<year>2013</year>
<volume>80</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Swerdlow]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2008 WHO classification of lymphoid neoplasms and be-yond: evolving concepts and practical applications]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>117</volume>
<page-range>5019-32</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ning Jiang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hua Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognosis factors research on the 172 non-hodgkin lymphoma cases.]]></article-title>
<source><![CDATA[Biomedical Research]]></source>
<year>2016</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>336-44</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pozzi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marcheselli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Federico]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tucci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Merli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab in Combination With Fludarabine and Cyclophosphamide in the Treatment of Patients With Recurrent Follicular Lymphoma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2007</year>
<volume>110</volume>
<page-range>121-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Jejunum Non-Hodgkin&#8217;s Diffuse Large B cell Lymphoma: an Origin of Extra-Germinal Center]]></article-title>
<source><![CDATA[Int J Cancer Cell Biol Res]]></source>
<year>2017</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>001-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sicras Mainar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro Artieda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas y respuesta al tratamiento de pacientes adultos con leucemia linfática crónica (LLC) y linfoma no Hodgkin (LNH)]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2016</year>
<volume>152</volume>
<page-range>59-69</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Álvarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterización clínica y biológica del proceso de transformación de los síndromes linfoproliferativos indolentes. Análisis histológico, fenotípico y molecular]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Salamanca ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Salamanca]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>American Cancer Society</collab>
<source><![CDATA[Non-Hodgkin Lymphoma Treatment. ACS]]></source>
<year>2015</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>664-71</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tse]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kwong]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent Advances in the Treatment of Lymphomas]]></article-title>
<source><![CDATA[J Hong Kong Col Radiol]]></source>
<year>2010</year>
<volume>13</volume>
<numero>Suppl</numero>
<issue>Suppl</issue>
<page-range>22-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foussard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Colombat]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Deconinck]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Original article long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as fi rst-line treatment of elderly patients with advanced, low-grade non-Hodgkin&#8217;s lymphoma before the era of monoclonal antibodies; on behalf of the Groupe Ouest-Est des Leucemies et Autres Maladies du Sang (GOELAMS).]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2005</year>
<volume>16</volume>
<page-range>466-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zinzani]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Pulsoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perrotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2004</year>
<volume>22</volume>
<page-range>2654-61</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labardini Méndez]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera Ceballos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales Alfaro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Balbuena Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa Ibarra]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza Zamora]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncoguía: Linfoma No Hodgkin. Cancerología 6]]></source>
<year>2011</year>
<page-range>139-52</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arcaini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Merli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Passamonti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2010</year>
<volume>149</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>455-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luminari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bellei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Biasoli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Federico]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Follicular lymphoma: treatment and prognostic factors]]></article-title>
<source><![CDATA[Rev Bras Hematol Hemoter]]></source>
<year>2012</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Redman]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Cabanillas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Velasques]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase II trial of fludarabine phosphate in lymphoma: an effective agent in low grade lymphoma]]></article-title>
<source><![CDATA[JCO]]></source>
<year>2012</year>
<volume>10</volume>
<page-range>790-4</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cencini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fabbri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schiattone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bartalucci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bocchia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2015</year>
<volume>56</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2997-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<collab>Physician Data Query</collab>
<source><![CDATA[Tratamiento del linfoma no Hodgkin en adultos]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Bethesda, MD ]]></publisher-loc>
<publisher-name><![CDATA[National Cancer Institute]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
